Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

Leukemia. 2023 Jan;37(1):1-4. doi: 10.1038/s41375-022-01779-8. Epub 2022 Dec 8.

Authors

Jean-Sébastien Claveau¹, David L Murray^{1

2}, Angela Dispenzieri¹, Prashant Kapoor¹, Moritz Binder¹, Francis Buadi¹, David Dingli¹, Amie Fonder¹, Morie Gertz¹, Wilson Gonsalves¹, Suzanne Hayman¹, Miriam Hobbs¹, Yi Lisa Hwa¹, Taxiarchis Kourelis¹, Martha Lacy¹, Nelson Leung¹, Yi Lin¹, Rahma Warsame¹, Robert A Kyle¹, Vincent Rajkumar¹, Shaji K Kumar³

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Department of Laboratory, Mayo Clinic, Rochester, MN, USA.
³ Division of Hematology, Mayo Clinic, Rochester, MN, USA. Kumar.Shaji@mayo.edu.

PMID: 36482129
DOI: 10.1038/s41375-022-01779-8

No abstract available

Publication types

Editorial

MeSH terms

Bone Marrow
Bone Marrow Examination
Humans
Mass Spectrometry
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy